|Videos|February 7, 2023
Selecting the Appropriate CAR T-Cell Therapy for Patients with R/R LBCL
Author(s)Loretta J. Nastoupil, MD, Marc S. Hoffmann, MD
Marc S. Hoffman, MD, explains how to select the appropriate CAR T-cell therapy for each patient, and the barriers patients with R/R LBCL face in receiving CAR T-cell therapy, despite its high efficacy rate.
Advertisement
Episodes in this series
Advertisement
Related to this article
The first MRD data from the phase 3 EXCALIBER-RRMM trial support iberdomide-based triplet therapy as early as first relapse, with PFS follow-up ongoing.
After nearly 7 years of follow-up, daratumumab added to VRd continued to improve PFS, PFS2, and sustained MRD negativity in transplant-eligible myeloma.
Monthly etentamig significantly improved response and PFS over standard available therapies in the phase 3 CERVINO trial, with low rates of high-grade CRS.
Extended follow-up from the phase 1b CAMMA 1 trial showed durable responses across two cevostamab dose levels, supporting selection of a recommended phase 3 regimen.
A MAIC found anito-cel produced response rates similar to those of cilta-cel, with fewer high-grade toxicities, in relapsed/refractory multiple myeloma.
Updated phase 2 LINKER-SMM1 data show single-agent, fixed-duration linvoseltamab produced deep, durable, and MRD-negative responses in high-risk smoldering multiple myeloma.
Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
Tegavivint Plus Osimertinib Shows Early Activity in First-Line EGFR-Mutated NSCLC
3
Etentamig Improves Response and PFS vs Standard Therapies in Triple-Class Exposed Relapsed/Refractory Myeloma
4
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
5